Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Gets OK to Float on NYSE

NEW YORK (GenomeWeb News) – Myriad Genetics today said that it has received approval to file an application transferring its shares from the Nasdaq stock exchange to the New York Stock Exchange.
 
The Salt Lake City-based developer of molecular diagnostics and therapeutics said that it expects to be trading on the NYSE Big Board in the second quarter of 2009. Once the transfer is complete, Myriad will trade under the symbol MGX.
 
Myriad had announced in October that it would spin off its drug development businesses from its molecular diagnostics business, creating two separate publicly traded firms. Myriad Pharmaceuticals will be listed on the NASDAQ Global Market under the company's current ticker symbol, MYGN.
 
Myriad officials recently said that the firm would likely use between $150 million and $200 million of the firm’s cash on hand to initially fund its pharma business.
 
 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.